 | • レポートコード：GIR-105X03147 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、がん免疫治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。がん免疫治療の種類別市場規模（モノクローナル抗体（MAB）、癌ワクチン、免疫調節剤、養子細胞移植、チェックポイント阻害剤）、用途別市場規模（乳がん、白血病、リンパ腫、黒色腫、結腸直腸がん、非小細胞肺がん）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・がん免疫治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amgen、AstraZeneca、Roche、Bristol-Myers Squibb、Bayer、Merck、ARMO BioSciences (Eli Lilly)、Novartis、Pfizer、Johnson & Johnson、AbbVie、Gilead Sciences ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：モノクローナル抗体（MAB）、癌ワクチン、免疫調節剤、養子細胞移植、チェックポイント阻害剤 ・用途別分析2016年-2026年：乳がん、白血病、リンパ腫、黒色腫、結腸直腸がん、非小細胞肺がん ・がん免疫治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・がん免疫治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・がん免疫治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・がん免疫治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・がん免疫治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Cancer Immunotherapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Cancer Immunotherapies size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Cancer Immunotherapies market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Cancer Immunotherapies market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monoclonal Antibodies (MABs)
Cancer Vaccines
Immunomodulators
Adoptive Cell transfer
Checkpoint Inhibitors
Market segment by Application can be divided into
Breast Cancer
Leukemia
Lymphoma
Melanoma
Colorectal Cancer
Non-Small Cell Lung Cancer
The key market players for global Cancer Immunotherapies market are listed below:
Amgen
AstraZeneca
Roche
Bristol-Myers Squibb
Bayer
Merck
ARMO BioSciences (Eli Lilly)
Novartis
Pfizer
Johnson & Johnson
AbbVie
Gilead Sciences
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Cancer Immunotherapies Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Cancer Immunotherapies Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global Cancer Immunotherapies Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Global Cancer Immunotherapies Market Size & Forecast
1.4.1 Global Cancer Immunotherapies Sales in Value (2016-2026))
1.4.2 Global Cancer Immunotherapies Sales in Volume (2016-2026)
1.4.3 Global Cancer Immunotherapies Price by Type (2016-2026) & (USD/Unit)
1.5 Global Cancer Immunotherapies Production Capacity Analysis
1.5.1 Global Cancer Immunotherapies Total Production Capacity (2016-2026)
1.5.2 Global Cancer Immunotherapies Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Cancer Immunotherapies Market Drivers
1.6.2 Cancer Immunotherapies Market Restraints
1.6.3 Cancer Immunotherapies Trends Analysis
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Cancer Immunotherapies Product and Services
2.1.4 Amgen Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Cancer Immunotherapies Product and Services
2.2.4 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Cancer Immunotherapies Product and Services
2.3.4 Roche Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Cancer Immunotherapies Product and Services
2.4.4 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Cancer Immunotherapies Product and Services
2.5.4 Bayer Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Cancer Immunotherapies Product and Services
2.6.4 Merck Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 ARMO BioSciences (Eli Lilly)
2.7.1 ARMO BioSciences (Eli Lilly) Details
2.7.2 ARMO BioSciences (Eli Lilly) Major Business
2.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product and Services
2.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Cancer Immunotherapies Product and Services
2.8.4 Novartis Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Cancer Immunotherapies Product and Services
2.9.4 Pfizer Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson Cancer Immunotherapies Product and Services
2.10.4 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Cancer Immunotherapies Product and Services
2.11.4 AbbVie Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.12 Gilead Sciences
2.12.1 Gilead Sciences Details
2.12.2 Gilead Sciences Major Business
2.12.3 Gilead Sciences Cancer Immunotherapies Product and Services
2.12.4 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Cancer Immunotherapies Sales by Manufacturer
3.1 Global Cancer Immunotherapies Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Cancer Immunotherapies Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Cancer Immunotherapies
3.4 Market Concentration Rate
3.4.1 Top 3 Cancer Immunotherapies Manufacturer Market Share
3.4.2 Top 6 Cancer Immunotherapies Manufacturer Market Share
3.5 Global Cancer Immunotherapies Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Cancer Immunotherapies Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Cancer Immunotherapies Market Size by Region
4.1.1 Global Cancer Immunotherapies Sales in Volume by Region (2016-2026)
4.1.2 Global Cancer Immunotherapies Revenue by Region (2016-2026)
4.2 North America Cancer Immunotherapies Revenue (2016-2026)
4.3 Europe Cancer Immunotherapies Revenue (2016-2026)
4.4 Asia-Pacific Cancer Immunotherapies Revenue (2016-2026)
4.5 South America Cancer Immunotherapies Revenue (2016-2026)
4.6 Middle East and Africa Cancer Immunotherapies Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Cancer Immunotherapies Sales in Volume by Type (2016-2026)
5.2 Global Cancer Immunotherapies Revenue by Type (2016-2026)
5.3 Global Cancer Immunotherapies Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Cancer Immunotherapies Sales in Volume by Application (2016-2026)
6.2 Global Cancer Immunotherapies Revenue by Application (2016-2026)
6.3 Global Cancer Immunotherapies Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Cancer Immunotherapies Sales by Type (2016-2026)
7.2 North America Cancer Immunotherapies Sales by Application (2016-2026)
7.3 North America Cancer Immunotherapies Market Size by Country
7.3.1 North America Cancer Immunotherapies Sales in Volume by Country (2016-2026)
7.3.2 North America Cancer Immunotherapies Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Cancer Immunotherapies Sales by Type (2016-2026)
8.2 Europe Cancer Immunotherapies Sales by Application (2016-2026)
8.3 Europe Cancer Immunotherapies Market Size by Country
8.3.1 Europe Cancer Immunotherapies Sales in Volume by Country (2016-2026)
8.3.2 Europe Cancer Immunotherapies Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Cancer Immunotherapies Sales by Type (2016-2026)
9.2 Asia-Pacific Cancer Immunotherapies Sales by Application (2016-2026)
9.3 Asia-Pacific Cancer Immunotherapies Market Size by Region
9.3.1 Asia-Pacific Cancer Immunotherapies Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Cancer Immunotherapies Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Cancer Immunotherapies Sales by Type (2016-2026)
10.2 South America Cancer Immunotherapies Sales by Application (2016-2026)
10.3 South America Cancer Immunotherapies Market Size by Country
10.3.1 South America Cancer Immunotherapies Sales in Volume by Country (2016-2026)
10.3.2 South America Cancer Immunotherapies Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Cancer Immunotherapies Sales by Type (2016-2026)
11.2 Middle East & Africa Cancer Immunotherapies Sales by Application (2016-2026)
11.3 Middle East & Africa Cancer Immunotherapies Market Size by Country
11.3.1 Middle East & Africa Cancer Immunotherapies Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Cancer Immunotherapies Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Cancer Immunotherapies Typical Distributors
12.3 Cancer Immunotherapies Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Cancer Immunotherapies Revenue by Type, (USD Million), 2021-2026
Table 2. Global Cancer Immunotherapies Revenue by Application, (USD Million), 2021-2026
Table 3. Amgen Basic Information, Manufacturing Base and Competitors
Table 4. Amgen Major Business
Table 5. Amgen Cancer Immunotherapies Product and Services
Table 6. Amgen Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca Cancer Immunotherapies Product and Services
Table 10. AstraZeneca Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Roche Basic Information, Manufacturing Base and Competitors
Table 12. Roche Major Business
Table 13. Roche Cancer Immunotherapies Product and Services
Table 14. Roche Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 16. Bristol-Myers Squibb Major Business
Table 17. Bristol-Myers Squibb Cancer Immunotherapies Product and Services
Table 18. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bayer Basic Information, Manufacturing Base and Competitors
Table 20. Bayer Major Business
Table 21. Bayer Cancer Immunotherapies Product and Services
Table 22. Bayer Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Merck Basic Information, Manufacturing Base and Competitors
Table 24. Merck Major Business
Table 25. Merck Cancer Immunotherapies Product and Services
Table 26. Merck Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. ARMO BioSciences (Eli Lilly) Basic Information, Manufacturing Base and Competitors
Table 28. ARMO BioSciences (Eli Lilly) Major Business
Table 29. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product and Services
Table 30. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Novartis Basic Information, Manufacturing Base and Competitors
Table 32. Novartis Major Business
Table 33. Novartis Cancer Immunotherapies Product and Services
Table 34. Novartis Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Pfizer Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer Cancer Immunotherapies Product and Services
Table 38. Pfizer Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 40. Johnson & Johnson Major Business
Table 41. Johnson & Johnson Cancer Immunotherapies Product and Services
Table 42. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. AbbVie Basic Information, Manufacturing Base and Competitors
Table 44. AbbVie Major Business
Table 45. AbbVie Cancer Immunotherapies Product and Services
Table 46. AbbVie Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 48. Gilead Sciences Major Business
Table 49. Gilead Sciences Cancer Immunotherapies Product and Services
Table 50. Gilead Sciences Cancer Immunotherapies Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Global Cancer Immunotherapies Sales by Manufacturer (2019-2021e) & (K Units)
Table 52. Global Cancer Immunotherapies Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 53. Market Position of Manufacturers in Cancer Immunotherapies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 54. Global Cancer Immunotherapies Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and Cancer Immunotherapies Production Site of Key Manufacturer
Table 56. Global Cancer Immunotherapies Sales by Region (2016-2021e) & (K Units)
Table 57. Global Cancer Immunotherapies Sales by Region (2021-2026) & (K Units)
Table 58. Global Cancer Immunotherapies Revenue by Region (2016-2021e) & (USD Million)
Table 59. Global Cancer Immunotherapies Revenue by Region (2021-2026) & (USD Million)
Table 60. Global Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 61. Global Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 62. Global Cancer Immunotherapies Revenue by Type (2016-2021e) & (USD Million)
Table 63. Global Cancer Immunotherapies Revenue by Type (2021-2026) & (USD Million)
Table 64. Global Cancer Immunotherapies Price by Type (2016-2021e) & (USD/Unit)
Table 65. Global Cancer Immunotherapies Price by Type (2021-2026) & (USD/Unit)
Table 66. Global Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 67. Global Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 68. Global Cancer Immunotherapies Revenue by Application (2016-2021e) & (USD Million)
Table 69. Global Cancer Immunotherapies Revenue by Application (2021-2026) & (USD Million)
Table 70. Global Cancer Immunotherapies Price by Application (2016-2021e) & (USD/Unit)
Table 71. Global Cancer Immunotherapies Price by Application (2021-2026) & (USD/Unit)
Table 72. North America Cancer Immunotherapies Sales by Country (2016-2021e) & (K Units)
Table 73. North America Cancer Immunotherapies Sales by Country (2021-2026) & (K Units)
Table 74. North America Cancer Immunotherapies Revenue by Country (2016-2021e) & (USD Million)
Table 75. North America Cancer Immunotherapies Revenue by Country (2021-2026) & (USD Million)
Table 76. North America Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 77. North America Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 78. North America Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 79. North America Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 80. Europe Cancer Immunotherapies Sales by Country (2016-2021e) & (K Units)
Table 81. Europe Cancer Immunotherapies Sales by Country (2021-2026) & (K Units)
Table 82. Europe Cancer Immunotherapies Revenue by Country (2016-2021e) & (USD Million)
Table 83. Europe Cancer Immunotherapies Revenue by Country (2021-2026) & (USD Million)
Table 84. Europe Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 85. Europe Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 86. Europe Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 87. Europe Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 88. Asia-Pacific Cancer Immunotherapies Sales by Region (2016-2021e) & (K Units)
Table 89. Asia-Pacific Cancer Immunotherapies Sales by Region (2021-2026) & (K Units)
Table 90. Asia-Pacific Cancer Immunotherapies Revenue by Region (2016-2021e) & (USD Million)
Table 91. Asia-Pacific Cancer Immunotherapies Revenue by Region (2021-2026) & (USD Million)
Table 92. Asia-Pacific Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 93. Asia-Pacific Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 94. Asia-Pacific Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 95. Asia-Pacific Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 96. South America Cancer Immunotherapies Sales by Country (2016-2021e) & (K Units)
Table 97. South America Cancer Immunotherapies Sales by Country (2021-2026) & (K Units)
Table 98. South America Cancer Immunotherapies Revenue by Country (2016-2021e) & (USD Million)
Table 99. South America Cancer Immunotherapies Revenue by Country (2021-2026) & (USD Million)
Table 100. South America Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 101. South America Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 102. South America Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 103. South America Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 104. Middle East & Africa Cancer Immunotherapies Sales by Country (2016-2021e) & (K Units)
Table 105. Middle East & Africa Cancer Immunotherapies Sales by Country (2021-2026) & (K Units)
Table 106. Middle East & Africa Cancer Immunotherapies Revenue by Country (2016-2021e) & (USD Million)
Table 107. Middle East & Africa Cancer Immunotherapies Revenue by Country (2021-2026) & (USD Million)
Table 108. Middle East & Africa Cancer Immunotherapies Sales by Type (2016-2021e) & (K Units)
Table 109. Middle East & Africa Cancer Immunotherapies Sales by Type (2021-2026) & (K Units)
Table 110. Middle East & Africa Cancer Immunotherapies Sales by Application (2016-2021e) & (K Units)
Table 111. Middle East & Africa Cancer Immunotherapies Sales by Application (2021-2026) & (K Units)
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Cancer Immunotherapies Typical Distributors
Table 115. Cancer Immunotherapies Typical Customers
List of Figures
Figure 1. Cancer Immunotherapies Picture
Figure 2. Global Cancer Immunotherapies Sales Market Share by Type in 2020
Figure 3. Monoclonal Antibodies (MABs)
Figure 4. Cancer Vaccines
Figure 5. Immunomodulators
Figure 6. Adoptive Cell transfer
Figure 7. Checkpoint Inhibitors
Figure 8. Global Cancer Immunotherapies Sales Market Share by Application in 2020
Figure 9. Breast Cancer
Figure 10. Leukemia
Figure 11. Lymphoma
Figure 12. Melanoma
Figure 13. Colorectal Cancer
Figure 14. Non-Small Cell Lung Cancer
Figure 15. Global Cancer Immunotherapies Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 16. Global Cancer Immunotherapies Market Size and Forecast (2016-2026) & (USD Million)
Figure 17. United States Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Canada Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Mexico Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Germany Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. France Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. United Kingdom Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Russia Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Italy Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. China Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Japan Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Korea Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. India Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Southeast Asia Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Australia Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Brazil Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Egypt Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Saudi Arabia Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. South Africa Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Turkey Cancer Immunotherapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Global Cancer Immunotherapies Sales (2016-2026) & (K Units)
Figure 37. Global Cancer Immunotherapies Production Capacity (2016-2026) & (K Units)
Figure 38. Global Cancer Immunotherapies Production Capacity by Geographic Region: 2020 VS 2021
Figure 39. Cancer Immunotherapies Market Drivers
Figure 40. Cancer Immunotherapies Market Restraints
Figure 41. Cancer Immunotherapies Market Trends
Figure 42. Global Cancer Immunotherapies Sales Market Share by Manufacturer in 2020
Figure 43. Global Cancer Immunotherapies Revenue Market Share by Manufacturer in 2020
Figure 44. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 45. Top 3 Cancer Immunotherapies Manufacturer (Revenue) Market Share in 2020
Figure 46. Top 6 Cancer Immunotherapies Manufacturer (Revenue) Market Share in 2020
Figure 47. Global Cancer Immunotherapies Sales Market Share by Region (2016-2026)
Figure 48. Global Cancer Immunotherapies Revenue Market Share by Region (2016-2026)
Figure 49. North America Cancer Immunotherapies Revenue (2016-2026) & (USD Million)
Figure 50. Europe Cancer Immunotherapies Revenue (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Cancer Immunotherapies Revenue (2016-2026) & (USD Million)
Figure 52. South America Cancer Immunotherapies Revenue (2016-2026) & (USD Million)
Figure 53. Middle East & Africa Cancer Immunotherapies Revenue (2016-2026) & (USD Million)
Figure 54. Global Cancer Immunotherapies Sales Market Share by Type (2016-2026)
Figure 55. Global Cancer Immunotherapies Revenue Market Share by Type (2016-2026)
Figure 56. Global Cancer Immunotherapies Price by Type (2016-2026) & (USD/Unit)
Figure 57. Global Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 58. Global Cancer Immunotherapies Revenue Market Share by Application (2016-2026)
Figure 59. Global Cancer Immunotherapies Price by Application (2016-2026) & (USD/Unit)
Figure 60. North America Cancer Immunotherapies Sales Market Share by Country (2016-2026)
Figure 61. North America Cancer Immunotherapies Revenue Market Share by Country (2016-2026)
Figure 62. North America Cancer Immunotherapies Sales Market Share by Type (2016-2026)
Figure 63. North America Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 64. Europe Cancer Immunotherapies Sales Market Share by Country (2016-2026)
Figure 65. Europe Cancer Immunotherapies Revenue Market Share by Country (2016-2026)
Figure 66. Europe Cancer Immunotherapies Sales Market Share by Type (2016-2026)
Figure 67. Europe Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 68. Asia-Pacific Cancer Immunotherapies Sales Market Share by Region (2016-2026)
Figure 69. Asia-Pacific Cancer Immunotherapies Revenue Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Cancer Immunotherapies Sales Market Share by Region (2016-2026)
Figure 71. Asia-Pacific Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 72. South America Cancer Immunotherapies Sales Market Share by Country (2016-2026)
Figure 73. South America Cancer Immunotherapies Revenue Market Share by Country (2016-2026)
Figure 74. South America Cancer Immunotherapies Sales Market Share by Type (2016-2026)
Figure 75. South America Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 76. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2016-2026)
Figure 77. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2016-2026)
Figure 78. Middle East & Africa Cancer Immunotherapies Sales Market Share by Type (2016-2026)
Figure 79. Middle East & Africa Cancer Immunotherapies Sales Market Share by Application (2016-2026)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
乳がん治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Breast cancer is cancer that forms in the cells of the breasts.Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly p…- 世界の癌用二重特異性抗体市場 2021：企業別、地域別、種類・用途別 The Bispecific Antibodies for Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 腎臓がんの薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer devel…
- 世界の乳がん治療薬市場 2021：企業別、地域別、種類・用途別 The Breast Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…
- がん幹細胞の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through gen…